Journal article
Cell-free circulating RAS mutation concentrations significantly impact the survival of metastatic colorectal cancer patients
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, v 149(9), p6435
Aug 2023
PMID: 36763171
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
PurposeRAS mutations are predictors of an adverse outcome in EGFR-targeted therapies and have been proposed as prognostic biomarkers of survival in metastatic colorectal cancer (mCRC). The analysis of circulating tumor DNA from plasma samples, known as liquid biopsies, has indicated that the RAS mutation status may change over time, potentially affecting patients' prognosis. To further evaluate the clinical validity of RAS mutation retesting using liquid biopsies, we prospectively investigated the impact of the circulating quantitative RAS mutation status on the course of mCRC.MethodsThe present study included 81 consecutively recruited patients with mCRC. We used targeted next-generation sequencing of circulating cell-free DNA to determine and quantify plasma RAS mutation status.ResultsPatients with a RAS mutation detected by liquid biopsy (37%; n = 30) were at increased risk of death during the follow-up period compared to RAS wild-type patients. Patients with evidence of a RAS mutation in the primary tumor but a putative RAS mutation loss in plasma (28%; n = 11) showed a prolonged survival compared to patients with a preserved RAS mutation status. Also, circulating RAS mutation concentrations significantly affected the outcome: The mortality risk of patients with a high RAS mutation concentration increased fivefold compared to subjects with a putative RAS mutation loss or low RAS mutation concentration.ConclusionOur results emphasize the clinical value of circulating RAS mutations in managing mCRC.
Metrics
Details
- Title
- Cell-free circulating RAS mutation concentrations significantly impact the survival of metastatic colorectal cancer patients
- Publication Details
- JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, v 149(9), p6435
- Publisher
- SPRINGER; NEW YORK
- Grant note
- The present study was partly financed by the European Union's European Regional Development Fund through the INTER-REG V program Alpenrhein-Bodensee-Hochrhein under Project No. ABH055.
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- Drexel University
- Web of Science ID
- WOS:000931837300003
- Scopus ID
- 2-s2.0-85147755659
- Other Identifier
- 991021860732304721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- International collaboration
- Web of Science research areas
- Oncology